ES2156107T3 - Un fgf-4 no glicosilado y composiciones que lo contienen. - Google Patents

Un fgf-4 no glicosilado y composiciones que lo contienen.

Info

Publication number
ES2156107T3
ES2156107T3 ES91900453T ES91900453T ES2156107T3 ES 2156107 T3 ES2156107 T3 ES 2156107T3 ES 91900453 T ES91900453 T ES 91900453T ES 91900453 T ES91900453 T ES 91900453T ES 2156107 T3 ES2156107 T3 ES 2156107T3
Authority
ES
Spain
Prior art keywords
fgf
glycosilated
compositions containing
glycosylated fgf
musculo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900453T
Other languages
English (en)
Inventor
David Thomas Rogers
Neil M Wolfman
Jasbir S Seehra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Application granted granted Critical
Publication of ES2156107T3 publication Critical patent/ES2156107T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN FGF-4 NO GLICOSADO, FGF-4 NO GLICOSADO HOMOGENEO Y PROCESOS PARA SU PRODUCCION. SE DESCRIBEN TAMBIEN COMPOSICIONES FARMACEUTICAS PARA USAR EN EL TRATAMIENTO DE DAÑOS EN EL TEJIDO SUAVE Y ENFERMEDADES DEL ESQUELETO MUSCULOSO EN MAMIFEROS.
ES91900453T 1989-11-16 1990-11-15 Un fgf-4 no glicosilado y composiciones que lo contienen. Expired - Lifetime ES2156107T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/438,278 US5126323A (en) 1989-11-16 1989-11-16 Homogeneous purified k-fgf and compositions containing the same

Publications (1)

Publication Number Publication Date
ES2156107T3 true ES2156107T3 (es) 2001-06-16

Family

ID=23739996

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900453T Expired - Lifetime ES2156107T3 (es) 1989-11-16 1990-11-15 Un fgf-4 no glicosilado y composiciones que lo contienen.

Country Status (11)

Country Link
US (2) US5126323A (es)
EP (2) EP0835932A1 (es)
JP (1) JP3020605B2 (es)
AT (1) ATE199167T1 (es)
AU (1) AU642947B2 (es)
CA (1) CA2068871C (es)
DE (1) DE69033703T2 (es)
DK (1) DK0500773T3 (es)
ES (1) ES2156107T3 (es)
GR (1) GR3035682T3 (es)
WO (1) WO1991007491A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750659A (en) * 1987-06-16 1998-05-12 New York University Mammalian growth factor
US5459250A (en) * 1987-06-16 1995-10-17 New York University Truncated mammalian growth factor DNA sequence
US6355781B1 (en) * 1987-06-16 2002-03-12 New York University Mammalian growth factor
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
NO921495L (no) * 1991-04-16 1992-10-19 Seikagaku Kogyo Co Ltd Oligosakkarid og fremgangsmaate for dets fremstilling
AU4645993A (en) * 1992-06-22 1994-01-24 New York University Mammalian growth factor
US5550114A (en) 1993-04-02 1996-08-27 Thomas Jefferson University Epidermal growth factor inhibitor
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US6455283B1 (en) 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
EP1121141A2 (en) 1998-10-13 2001-08-08 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
DE60036937T2 (de) 1999-04-28 2008-08-07 Genetics Institute, LLC, Cambridge HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE
PT1054018E (pt) 1999-05-18 2009-02-16 Dyax Corp Bibliotecas de fragmentos fab e métodos para a sua utilização
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2005012530A2 (en) 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
WO1987001728A1 (en) * 1985-09-12 1987-03-26 Biotechnology Research Partners, Ltd. Recombinant fibroblast growth factors
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
JPH01501840A (ja) * 1987-01-16 1989-06-29 アムジエン・インコーポレーテツド 繊維芽細胞成長因子の産生
NZ226543A (en) * 1987-10-22 1992-02-25 Merck & Co Inc Recombinant mutant acidic fibroblast growth factor
DE68909254T2 (de) * 1988-01-25 1994-04-28 American Cyanamid Co Heparinbindende Gehirnmitogene.
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same

Also Published As

Publication number Publication date
DE69033703D1 (de) 2001-03-22
CA2068871C (en) 2003-02-11
US5126323A (en) 1992-06-30
GR3035682T3 (en) 2001-06-29
JP3020605B2 (ja) 2000-03-15
DK0500773T3 (da) 2001-06-18
WO1991007491A1 (en) 1991-05-30
EP0500773A1 (en) 1992-09-02
US5430019A (en) 1995-07-04
CA2068871A1 (en) 1991-05-17
JPH05503090A (ja) 1993-05-27
EP0500773B1 (en) 2001-02-14
AU642947B2 (en) 1993-11-04
ATE199167T1 (de) 2001-02-15
AU6894291A (en) 1991-06-13
DE69033703T2 (de) 2001-09-13
EP0835932A1 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
EP0236684A3 (en) Galanthamine or analogues thereof for treating alzheimer's disease
DE69101080D1 (de) Diätfaser, Verfahren und physiologische aktive Zusammensetzung, die diese als aktives Ingredient enhält.
NO931635D0 (no) Fremgangsmaate for fremstilling av kinazolin-derivater
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
ES2082872T3 (es) Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol.
BG101040A (en) Benzopyrans and their use as therapeutic agents
IL89662A (en) Pharmaceutical compositions comprising interferon-beta
ATE119783T1 (de) Neue, nicht-ionische carboxamid-kontrastmittel.
ZA9010080B (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
EP0544802A4 (en) Methods and compositions for treating t-cell mediated diseases
ZA871032B (en) Pharmaceutical compositions for the therapy of cerebropatheis on functional and organic base
ATE311399T1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
GR3034414T3 (en) Pharmaceutical compositions comprising calcitonin.
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
YU47393A (sh) Novi derivati fosfolipida
ES541944A0 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
ZA893310B (en) Novel strobilurine derivatives,their preparation and their use
ES2081884T3 (es) Factor citotoxico oligodendrocitico.
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GR3005231T3 (es)
DK0608648T3 (da) Højdoserede vitamin A-præparater
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
ES2025787T3 (es) Procedimiento de tratamiento de madera.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 500773

Country of ref document: ES